Notice

HOME > INVERSTORS & NEWS > Notice

ISU Abxis Presentations at 2020 AACR Virtual Annual Meeting II

  • 관리자
  • 2020-05-20
  • 259

ISU Abxis Presentations at 2020 AACR Virtual Annual Meeting II


ISU Abxis Co., Ltd. (KOSDAQ: 086890) announced a poster presentation featuring pre-clinical evaluation data of the potential predictive biomarkers for ISU104 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II. ISU104 is a monoclonal human anti-ErbB3 antibody designed to inhibit ligand-dependent/independent dimerization of ErbB3 with other ErbBs and induces internalization of ErbB3, and subsequently inactivates the downstream signaling. ISU104 received IND for Phase 1 clinical study approval from MFDS in 2017, and is currently being tested in patients with head and neck.

 

Poster presentation details:


Title: Anti-cancer efficacy of an anti-ErbB3 antibody, ISU104, against the cancers with NRG1-overexpression, NRG1-fusion, or oncogenic ErbB3 mutations

Abstract number: 3042

Date and Time: June 22, 2020, 9am-6pm (EDT)

Presenter/Authors: Seung-Beom Hong, Mirim Hong, Tae-Eun Kim, Ju Yeon Kim, Jung Won Kim, Cho Jeongin, Bongseok Shin, Donggoo Bae. ISU Abxis Co., Ltd.

Session Category: Experimental and Molecular Therapeutics

Session Title: Targeting Tumor Microenvironment, Protein Kinases/Phosphatases, and Other Strategies

Link to the abstract: https://www.abstractsonline.com/pp8/#!/9045/presentation/5081